Motegrity and Anesthesia
Motegrity (prucalopride) can be safely continued throughout the perioperative period without specific contraindications related to anesthesia, though vigilance for serotonin syndrome is warranted when combined with other serotonergic agents.
Perioperative Management
Based on the FDA label and available evidence, there are no specific recommendations to hold Motegrity before surgery 1. The drug is a selective 5-HT4 receptor agonist used for chronic idiopathic constipation, and unlike medications explicitly addressed in perioperative guidelines (such as ergotamine, triptans, or butalbital), prucalopride is not listed among agents requiring discontinuation 2.
Key Safety Considerations
Serotonin Syndrome Risk
The primary anesthetic concern involves potential serotonin syndrome when prucalopride is combined with other serotonergic medications. Perioperative guidelines emphasize that serotonin syndrome risk increases with concurrent use of:
- Serotonergic opioids (fentanyl, meperidine, methadone, tramadol, tapentadol)
- Ondansetron and granisetron (commonly used antiemetics)
- Metoclopramide
- SSRIs, SNRIs, MAO inhibitors
- Other serotonergic agents 2
Monitor for neuroexcitatory symptoms, autonomic dysfunction, and neuromuscular abnormalities if multiple serotonergic agents are administered perioperatively.
Cardiovascular Safety
Extensive cardiovascular safety data demonstrates no significant concerns with prucalopride:
- No QT prolongation at therapeutic (2 mg) or supratherapeutic (10 mg) doses
- No trends in adverse cardiovascular events in phase 3 trials
- Real-world data from 35,087 patients showed no increased risk of major adverse cardiovascular events 3
This distinguishes prucalopride from first-generation 5-HT4 agonists that were withdrawn due to cardiac concerns.
Contraindications (Not Anesthesia-Specific)
The FDA label lists absolute contraindications that would preclude surgery regardless of medication continuation 1:
- Intestinal perforation or obstruction
- Obstructive ileus
- Severe inflammatory bowel conditions (Crohn's disease, ulcerative colitis)
- Toxic megacolon/megarectum
Practical Recommendations
Continue Motegrity perioperatively with the following precautions:
- Alert the anesthesiologist to prucalopride use, particularly if serotonergic opioids or antiemetics will be administered
- Minimize concurrent serotonergic agents when possible, or use alternatives (e.g., dexamethasone instead of ondansetron for PONV prophylaxis)
- Monitor for diarrhea postoperatively, as 70% of patients experience this in the first week of treatment, though it typically resolves within days 1
- Adjust dose in severe renal impairment (CrCl <30 mL/min): reduce to 1 mg daily 1
Common Pitfalls to Avoid
- Do not assume all prokinetics are contraindicated: Unlike metoclopramide (which has documented serotonin syndrome risk with certain combinations), prucalopride's selective 5-HT4 mechanism has a different safety profile 2
- Do not confuse with older 5-HT4 agonists: Cisapride and tegaserod were withdrawn for cardiac concerns; prucalopride has demonstrated cardiovascular safety 3
- Do not discontinue unnecessarily: Stopping may worsen constipation, particularly problematic with postoperative opioid use
The absence of specific perioperative management guidelines for prucalopride in major consensus statements 2, 4 combined with its favorable safety profile supports continuation throughout the surgical period.